News and Research

This landmark 2024 update synthesizes global evidence showing that up to 40-45% of dementia cases may be preventable by addressing 14 modifiable risk factors - including education, hearing and vision loss, hypertension, smoking, physical inactivity, diabetes, depression, social isolation, and air pollution.

A 2023 cross-sectional survey examining public awareness of 13 modifiable dementia risk factors among 551 Irish adults. Findings reveal critical awareness gaps: while head injury (90.9%), low mental stimulation (85.3%), and alcohol consumption (77.8%) were well recognized, many other key risk factors remained unknown. Results demonstrate that awareness levels vary significantly by education, gender, and age, emphasizing the need for tailored prevention messaging.

This 2022 validation study demonstrates BOCA's effectiveness as a self-administered digital cognitive assessment. Testing 100 participants (50 with cognitive impairment, 50 controls), the study confirmed strong discriminative ability between groups (p < 0.001), excellent test-retest reliability (R = 0.94), and minimal practice effects over 10 consecutive days. The 10-minute assessment evaluates eight cognitive domains and showed strong correlation with Montreal Cognitive Assessment (MoCA) (R = 0.90).

This pioneering 2024 randomized controlled trial demonstrated that comprehensive lifestyle modifications - including plant-based nutrition, exercise, stress management, and group support - produced measurable improvements in cognitive function and reduced disease progression in patients with mild cognitive impairment or early Alzheimer's disease over 20 weeks. The intervention group showed significant improvements across multiple cognitive assessments while the control group declined, with supporting evidence from biomarker changes including increased plasma amyloid ratios and beneficial microbiome modifications.

A 2026 retrospective case series describing an integrative, personalized functional-medicine approach to cognitive decline, drawn from the first 51 patients with mild cognitive impairment or Alzheimer's disease seen in an academic clinic. Among the 22 patients who remained in the program for at least 2.5 years, 73% showed improvement or stabilization on follow-up cognitive testing.

This 2025 randomized controlled trial of 6,104 Australian adults (aged 55-77) demonstrates that personalized online multidomain lifestyle coaching significantly improves cognitive outcomes over 3 years. Participants receiving tailored interventions in physical activity, nutrition, cognitive activity, and mental health showed significantly better global cognition (difference: 0.18 z-score, P < 0.001) compared to controls. The scalable digital intervention supports population-level dementia prevention.

This 2025 multicenter US randomized clinical trial of 2,111 older adults (60-79 years) at risk of cognitive decline demonstrates that structured, higher-intensity lifestyle interventions significantly outperform self-guided approaches. The structured intervention, targeting physical exercise, MIND diet adherence, cognitive challenge, social engagement, and cardiovascular health, produced greater improvement in global cognition (0.243 SD per year vs 0.213 SD per year; difference: 0.029 SD, P = .008) over 2 years. Results affirm the value of supervised, accountable programs like the Boston Cognitive Program.

This research examined the prevalence of cognitive impairment among 656 individuals receiving addiction treatment using the Montreal Cognitive Assessment (MoCA) screening tool. Results revealed that roughly one-third of patients experienced cognitive impairment. Those dependent on alcohol showed weaker memory performance compared to cannabis users, while opioid users displayed reduced spatial reasoning abilities versus cannabis or stimulant users. Age proved significant, with younger participants performing better than older ones. The researchers concluded that early cognitive screening should become standard practice at treatment initiation to enhance outcomes and support more effective interventions.

This 2025 longitudinal study analyzed data from 4,354 participants in the Framingham Heart Study, tracked for up to 40 years. Researchers found that high levels of physical activity in midlife (ages 45-64) were associated with a 41% lower dementia risk, while late-life exercise (ages 65-88) showed a 45% lower risk. The study identified "key windows" when exercise matters most for brain health, noting that vascular risk factors typically emerge in midlife. Notably, for those with the APOE ε4 genetic risk factor, late-life exercise provided protective benefits regardless of genetic predisposition. The WHO recommends 150 to 300 minutes of moderate aerobic activity weekly for brain health protection.

This 2025 study evaluates the Mandarin version of the Boston Cognitive Assessment (BoCA) as a screening tool for cognitive impairment in stroke survivors. Testing 120 stroke patients and 120 healthy controls, the study demonstrated strong internal consistency (Cronbach's alpha = 0.808) and excellent test-retest reliability (ICC = 0.895). BoCA scores strongly correlated with both MMSE (r = 0.829) and MoCA (r = 0.848), achieving 81.7% sensitivity and 69.2% specificity at a cutoff score of 23.5. The findings support BoCA as a valuable supplementary measure for cognitive assessment in stroke survivors through remote, self-administered testing.

This 2023 feasibility study examined whether non-invasive 40 Hz light and sound therapy delivered via tablet application could benefit patients with cognitive decline. Among completers, 4 of 11 participants showed improved MOCA scores in the Memory Index section. The study demonstrated that 40 Hz sensory therapy is tolerable with minimal side effects, supporting further exploration of this treatment modality in larger randomized controlled trials.

This 2022 study investigated gamma entrainment using sensory stimulation (GENUS) as a non-pharmacological approach for Alzheimer's disease. Researchers found that cognitive tasks during 40 Hz visual stimulation enhance neural entrainment and promote propagation to deeper brain regions including the hippocampus - a primary therapeutic target for Alzheimer's treatment. The findings suggest combining cognitive activities with 40 Hz stimulation may improve efficacy or reduce treatment duration.

This MIT research tested 40 Hz light and sound stimulation in Alzheimer's patients through two clinical studies. The first study confirmed the approach is safe and effectively stimulates brain activity. The second study with 15 patients showed daily use was well-tolerated and associated with slower brain volume loss, improved brain connectivity, better memory for faces and names, and more regular sleep-wake patterns compared to controls.

This 2025 Nature Medicine study of 296 cognitively unimpaired older adults demonstrates that higher physical activity - measured by pedometer step counts - is associated with slower cognitive and functional decline in individuals with elevated baseline amyloid. The beneficial effect was mediated by slower tau accumulation in the inferior temporal region, not reduced amyloid burden. Dose-response analyses revealed a curvilinear relationship, with associations reaching a plateau at moderate activity levels (5,001-7,500 steps per day), providing actionable targets for dementia prevention.